ea0092ps3-28-04 | Translational 2 | ETA2023
Martina Ferrari Silvia
, Elia Giusy
, Ragusa Francesca
, Rosaria Paparo Sabrina
, Mazzi Valeria
, Patrizio Armando
, Piaggi Simona
, Baldini Enke
, Centanni Marco
, La Motta Concettina
, Antonelli Alessandro
, Fallahi Poupak
Anaplastic thyroid cancer (ATC) is usually treated with surgery, external hyperfractionated radiation therapy, and chemotherapy. However, because of the aggressiveness of this type of cancer, these treatments allow about 6-10 months of median survival. Therefore, it is challenging to predict the ATC patient clinical therapy responsiveness. Pazopanib is a multitarget tyrosine kinase inhibitor of VEGF receptors, PDGF, and c-Kit, and its effect in primary human ATC cells (pATC) h...